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I
n the 19th century, lung cancer was an unusual tumor; so much so that single case reports of the rare cancer were published in the scientific literature of the day. Things have changed. Other than skin cancer, lung cancer is now the most common cancer and is the most frequent cause of death from cancer in both men and women.
In recognition of the importance of lung cancer in the population and with the rise of evidence-based medicine as a basis for diagnosing the disease and managing those afflicted, in the year 2000 the American College of Chest Physicians (ACCP), through its Health and Science Policy Committee, commissioned the development of evidence-based guidelines on the diagnosis and management of lung cancer. The goal was to assist physicians in achieving the best possible outcomes given the knowledge and capabilities available at the time. The size of the task was daunting, but the goal was laudable and the guidelines were successfully published as a Supplement to CHEST in January of 2003.
Fortunately, the pace of discovery in the diagnosis and management of lung cancer has quickened. As a result, the ACCP found it prudent to commission the development of a second edition of the guidelines. This guideline Supplement is the result of that effort and represents the work of nearly 100 voluntary faculty and ACCP staff.
The methodology and grading system used to develop the second edition of the guidelines may be found in a separate chapter. Rigorous adherence to formal guideline methodology was stressed. This attention to process detail and the use of the newly developed ACCP grading system has produced a valid, yet clinically useful document.
In response to suggestions made after the first edition, several new chapters have been added, such as "Diagnostic Surgical Pathology in Lung Cancer," "Bronchioloalveolar Lung Cancer," and "Complementary Therapies and Integrative Oncology in Lung Cancer." A number of chapters have been extensively reworked to encompass recent knowledge; for example, "Screening for Lung Cancer, Management of Patients with Pulmonary Nodules: When is it lung cancer?" (ie, the chapter previously termed the "Solitary Pulmonary Nodule"), "Bronchial Intraepithelial Neoplasia/Early Central Airways Lung Cancer" (ie, the chapter previously termed "The Treatment of Early Stage Non-small Cell Lung Cancer"), and "Palliative Care Consultation," "Quality of Life Measurement," and "Bereavement for End-of-Life Care in Patients with Lung Cancer." All of the chapters have incorporated information and knowledge gleaned from the literature published since 2002.
Recommendations from each of the chapters are listed below under their respective chapter titles. For an in-depth discussion or clarification of each recommendation, readers are encouraged to read the specific chapter in question in its entirety.
Summary of Recommendations
Lung Cancer Chemoprevention 1. For individuals with a Ͼ 20 -pack-year history of smoking or with a history of lung cancer, the use of beta-carotene supplementation is not recommended for primary, secondary, or tertiary chemoprevention of lung cancer. Grade of recommendation, 1A 2. For individuals at risk for lung cancer and for patients with a history of lung cancer, the use of vitamin E, retinoids, N-acetylcysteine, and aspirin is not recommended for primary, secondary, or tertiary prevention of lung cancer. Grade of recommendation, 1A
3. For individuals at risk for lung cancer or with a history of lung cancer, budenoside, cyclooxygenase-2 inhibitors, 5-lipoxygenase inhibitors, and prostaglandin analogs are not recommended for use for primary, secondary, or tertiary lung cancer chemoprevention outside of the setting of a well-designed clinical trial. Grade of recommendation, 2C
4. In individuals at risk for lung cancer or with a history of lung cancer, the use of oltipraz as a primary, secondary, or tertiary chemopreventive agent of lung cancer is not recommended. Grade of recommendation, 1B 5. For individuals at risk for lung cancer or with a history of lung cancer, the use of selenium, and anethole dithiolethione, for primary, secondary, or tertiary lung cancer chemoprevention is not recommended outside of the setting of a well-designed clinical trial. Grade of recommendation, 1B 4. In a patient with an SPN that is stable on imaging tests for at least 2 years, we suggest that no additional diagnostic evaluation be performed, except for patients with pure ground-glass opacities on CT, for whom a longer duration of annual follow-up should be considered. Grade of recommendation, 2C
5. In a patient with an SPN that is calcified in a clearly benign pattern, we recommend that no additional diagnostic evaluation is necessary. Grade of recommendation, 1C
6. In every patient with an indeterminate SPN that is visible on chest radiography, we recommend that CT of the chest should be performed, preferably with thin sections through the nodule. Grade of recommendation, 1C
7. In every patient with an indeterminate SPN that is visible on chest CT, we recommend that previous imaging tests should be reviewed. Grade of recommendation, 1C
8. In a patient with normal renal function and an indeterminate SPN on chest radiograph or chest CT, we recommend that CT with dynamic contrast enhancement be considered in centers with experience performing this technique. Grade of recommendation, 1B 9. In patients with low-to-moderate pretest probability of malignancy (5 to 60%) and an indeterminate SPN that measures at least 8 to 10 mm in diameter, we recommend that fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging should be performed to characterize the nodule. Grade of recommendation, 1B 10. In patients with an SPN that has a high pretest probability of malignancy (Ͼ 60%), or patients with a subcentimeter nodule that measures Ͻ 8 to 10 mm in diameter, we suggest that FDG-PET not be performed to characterize the nodule.
Grade of recommendation, 2C
11. In every patient with a SPN, we recommend that clinicians discuss the risks and benefits of alternative management strategies and elicit patient preferences. Grade of recommendation, 1C
12. In patients with an indeterminate SPN that measures at least 8 to 10 mm indiameter and who are candidates for curative treatment, observation with serial CT scans is an acceptable management strategy in the following circumstances:
• When the clinical probability of malignancy is very low (Ͻ 5%) 8. In NSCLC patients with N2 disease identified preoperatively (IIIA3) who do receive induction chemoradiotherapy as part of a clinical trial, pneumonectomy is not recommended. The subsequent surgical resection in this setting should be limited to a lobectomy. If after induction chemoradiotherapy it appears that a pneumonectomy will be needed, it is recommended that pneumonectomy not be performed and treatment should be continued with full-dose radiotherapy. Grade of recommendation, 1B 9. In NSCLC patients with N2 disease identified preoperatively (IIIA3), primary surgical resection followed by adjuvant therapy is not recommended except as part of a clinical trial. Grade of recommendation, 1C 
In patients with NSCLC who have bulky N2 disease (IIIA4) and good PS, radiotherapy alone is not recommended.

Grade of recommendation, 1A
15. In patients with NSCLC who have bulky N2 disease (IIIA4) and good PS, combination platinum-based chemotherapy and radiotherapy are recommended. Grade of recommendation, 1A
16. In patients with NSCLC who have bulky N2 disease (IIIA4), good PS, and minimal weight loss, concurrent chemoradiotherapy is recommended over sequential chemoradiotherapy. Grade of recommendation, 1A
Treatment of NSCLC Stage IIIB 1. In selected patients with clinical T4N0-1 NSCLC due to satellite tumor nodule(s) in the same lobe, carinal involvement, or superior vena cava (SVC) invasion, it is recommended that evaluation be performed by a multidisciplinary team that includes a thoracic surgeon with lung cancer expertise to determine if the patient is operable. Surgery is not recommended if there is N2 involvement. Grade of Recommendation, 1C
2. For patients with stage IIIB NSCLC due to N3 disease, treatment with neoadjuvant (induction) chemotherapy or chemoradiotherapy followed by surgery is not recommended. Grade of recommendation, 1C
3. For patients with stage IIIB disease without malignant pleural effusions, PS of 0 or 1, and minimal weight loss (< 5%), platinum-based combination chemotherapy is recommended. Grade of recommendation, 1A
4. In patients with stage IIIB NSCLC and PS of 2 or those with substantial weight loss (Ͼ 10%), chemoradiotherapy is recommended only after careful consideration.
Grade of recommendation, 1C
5. For stage IIIB NSCLC patients with PS of 0 or 1 and minimal weight loss (< 5%), concurrent chemoradiotherapy is recommended. Grade of recommendation, 1A
6. The most efficacious chemotherapy drugs to be combined with thoracic radiotherapy and the number of cycles of chemotherapy needed to yield the best results is currently uncertain. No one combination chemotherapy regimen can be recommended.
Grade of recommendation, 2C
7. For patients with stage IIIB NSCLC, once-daily thoracic radiotherapy plus chemotherapy is recommended. Grade of recommendation, 1B 8. For stage IIIB patients and either poor PS or disease too extensive to treat with curative intent and symptoms due to chest disease, palliative radiotherapy is recommended. The fractionation pattern should be chosen based on the physician's judgment and patient's needs. Grade of recommendation, 1A
Treatment of NSCLC Stage IV
1. In patients with stage IV NSCLC and a good PS, two-drug combination chemotherapy is recommended. The addition of a third cytotoxic chemotherapeutic agent is not recommended because it provides no survival benefit and may be harmful. Grade of recommendation, 1A 2. Bevacizumab improves survival combined with carboplatin and paclitaxel in a clinically selected subset of the good PS, stage IV NSCLC (nonsquamous histology, lack of brain metastases, and no hemoptysis). In these patients, bevacizumab added to carboplatin and paclitaxel should be considered a therapeutic option. Grade of recommendation, 1A
12. In patients with a T4N0,1M0 NSCLC, it is recommended that resection be undertaken only at a specialized center. Grade of recommendation, 1C
13. In patients with suspected or proven lung cancer and a satellite nodule within the same lobe, it is recommend that no further diagnostic workup of a satellite nodule is undertaken. Grade of recommendation, 1B 14. In patients with a satellite lesion within the same lobe as a suspected or proven primary lung cancer, evaluation of extrathoracic metastases and confirmation of the mediastinal node status should be performed as dictated by the primary lung cancer alone, and not modified due to the presence of the satellite lesion. Grade of recommendation, 1C
15. In patients with NSCLC and a satellite focus of cancer within the same lobe (and no mediastinal or distant metastases), resection via a lobectomy is the recommended treatment. Grade of recommendation, 1B
16. In patients with two synchronous primary NSCLCs being considered for curative surgical resection, invasive mediastinal staging and extrathoracic imaging (head CT/MRI plus either whole-body PET or abdominal CT plus bone scan) are recommended. Involvement of mediastinal nodes and/or metastatic disease represent a contraindication to resection. Grade of recommendation, 1C
17. In patients suspected of having two synchronous primary NSCLCs, a thorough search for an extrathoracic primary cancer to rule out the possibility that both of the lung lesions represent metastases is recommended. Grade of recommendation, 1C
18. In patients not suspected of having a second focus of cancer who are found intraoperatively to have a second cancer in a different lobe, resection of each lesion is recommended, provided the patient has adequate pulmonary reserve and there is no N2 nodal involvement. 
